secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K/A
Filed at:   2024-12-31T23:59:59+00:00
Accession:  0001193125-24-287065
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma grants COO Sophie Mukadam 300,000 options at $12.00
---------------------------------------------------------------------

- Sophie Mukadam appointed COO effective Jan 1, 2025; receives 300,000 nonqualified stock options.
- Exercise price $12.00 per share, equal to closing price on grant date Dec 27, 2024.
- Vesting in 16 equal quarterly installments starting Mar 31, 2025, conditioned on continued service.
- Unvested options fully accelerate upon a Change in Control as defined in the Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524287065/0001193125-24-287065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524287065/d905396d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-287065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer